Skip to main content
Premium Trial:

Request an Annual Quote

FDA Grants Emergency Use Authorizations for Quest Coronavirus Assays

NEW YORK — The US Food and Drug Administration on Wednesday issued Emergency Use Authorizations for three SARS-CoV-2 tests from Quest Diagnostics that use nasal swab self-collection devices.

Quest's PF SARS-CoV-2 Assay is performed using Hologic's Panther Fusion SARS-CoV-2 RT-PCR-based test, its RC SARS-CoV-2 Assay is performed using Roche's automated Cobas SARS-CoV-2 RT-PCR test, and its HA SARS-CoV-2 Assay is performed using Hologic's Aptima SARS-CoV-2 test.

All three tests are RT-PCR-based and have previously received EUA from the FDA.

According to the FDA, the three Quest assays use nasal swab samples collected using the company's Self-Collection Kit for COVID-19 or other authorized home-collection kit while observed by a healthcare provider via telemedicine.

Collected samples are shipped to Quest-designated laboratories CLIA-certified to perform high-complexity tests, the FDA said.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.